Taken together, while HER2-positive CADD frameworks are mainly directed toward refining established antibody and TKI therapies, TNBC strategies are being advanced through the use of transcriptional subtypes, tumor ecosystem features, and imaging-derived markers to inform novel drug design and patient selection. This evidence concerns the gene ERBB2 and neoplasm.